MoonLake Immunotherapeutics’ (MLTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in a research report report published on Friday morning,Benzinga reports. HC Wainwright currently has a $32.00 price objective on the stock, up from their prior price objective of $26.00.

Several other research analysts have also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a research note on Wednesday, October 8th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $10.00 target price (down from $67.00) on shares of MoonLake Immunotherapeutics in a report on Monday, September 29th. The Goldman Sachs Group reissued a “neutral” rating and set a $7.00 price target on shares of MoonLake Immunotherapeutics in a research report on Wednesday, October 1st. Jefferies Financial Group downgraded MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $8.00 price objective for the company. in a report on Monday, September 29th. Finally, Wolfe Research lowered shares of MoonLake Immunotherapeutics from an “outperform” rating to an “underperform” rating in a research note on Tuesday, September 30th. Seven investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $25.54.

MoonLake Immunotherapeutics Trading Up 28.9%

MLTX stock opened at $18.49 on Friday. The company has a market capitalization of $1.19 billion, a PE ratio of -5.57 and a beta of 1.21. MoonLake Immunotherapeutics has a 12 month low of $5.95 and a 12 month high of $62.75. The firm’s 50-day moving average is $13.18 and its 200 day moving average is $31.35. The company has a debt-to-equity ratio of 0.25, a current ratio of 8.50 and a quick ratio of 8.50.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.21). During the same quarter in the prior year, the firm earned ($0.56) EPS. On average, research analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Insiders Place Their Bets

In related news, insider Kristian Reich sold 72,908 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $14.43, for a total transaction of $1,052,062.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Da Silva Jorge Santos sold 70,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $14.49, for a total value of $1,014,300.00. Following the completion of the transaction, the chief executive officer owned 2,878,577 shares in the company, valued at $41,710,580.73. This trade represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 402,908 shares of company stock valued at $5,987,162 over the last 90 days. 12.05% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. FNY Investment Advisers LLC purchased a new stake in MoonLake Immunotherapeutics during the third quarter valued at approximately $28,000. Bank of America Corp DE increased its position in shares of MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after purchasing an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of MoonLake Immunotherapeutics by 115.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after purchasing an additional 3,166 shares during the last quarter. Covestor Ltd acquired a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter worth $46,000. Finally, BNP Paribas Financial Markets boosted its position in shares of MoonLake Immunotherapeutics by 18.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock worth $52,000 after purchasing an additional 1,158 shares in the last quarter. Institutional investors own 93.85% of the company’s stock.

Key Headlines Impacting MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: FDA feedback may allow a skin drug filing for SLK without new clinical trials, reducing regulatory risk and supporting a faster BLA path. MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars
• Positive Sentiment: HC Wainwright reaffirmed a Buy and raised its price target to $32, signaling stronger analyst conviction and giving investors a higher upside benchmark. Benzinga: HC Wainwright rating/price target
• Positive Sentiment: Needham maintained a Buy rating and $20 target, citing regulatory de‑risking on HS and 2026 inflammatory disease catalysts as supporting the investment case. MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating
• Positive Sentiment: Retail momentum and speculation about potential M&A conversations amplified the rally, attracting heavy trading volume and short‑term buying interest. MLTX stock extends rally as FDA feedback spurs bullish brokerage action – retail speculates on potential M&A conversations
• Neutral Sentiment: Analysts and commentators view the FDA Type B meeting as momentum ahead of a planned BLA submission; this is positive if regulators agree but not a guarantee of approval. MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission
• Neutral Sentiment: Explanatory pieces trace the pre‑market surge and investor interest — useful for context but not new catalyst information. Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Up 34.28%
• Negative Sentiment: Fundamentals remain loss‑making (recent EPS misses and negative forecasted EPS), and regulatory outcomes or labeling negotiations could still require additional data or post‑market commitments. Investors should weigh binary regulatory risk and past volatility. MarketBeat MLTX profile (financials & recent results)

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.